ZyVersa Therapeutics, Inc. (ZVSA) has announced new data showing that its Inflammasome ASC Inhibitor IC 100 significantly improves heart function, reduces inflammation, and restores glucose homeostasis in an obese animal model of heart failure with preserved ejection fraction or HFpEF and type 2 diabetes.
The data highlights the potential of IC 100 as a promising treatment for obesity-related cardiovascular and metabolic diseases.
The study found that IC 100 reduced cardiac inflammation, improved diastolic heart function, and decreased fat mass and adipocyte size.
It also enhanced insulin sensitivity and glucose regulation, positioning IC 100 as a therapeutic candidate for HFpEF and its comorbidities.
The research supports ZyVersa's ongoing efforts to leverage IC 100 in treating metabolic complications associated with obesity.
Currently, ZVSA is trading at $1.06 up by 1.45 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.